Literature DB >> 20201748

A role for CYP in the drug-hormone crosstalk of the brain.

Ralf Peter Meyer1, Marcel Gehlhaus.   

Abstract

IMPORTANCE OF THE FIELD: Libido disorders, menstruation problems, perception and cognition deficiencies are potentially undesired, but clinically emerging, side effects after long-term therapy with antiepileptic drugs or chemotherapeutic agents. These disorders were shown to occur predominantly in patients who had taken drugs interacting with the CYP system of the brain, particularly in the hippocampus, the hypothalamus, the cerebellum or in the amygdala. CYPs present and active in these regions usually inactivate steroid hormones such as testosterone. AREAS COVERED IN THIS REVIEW: The present review focuses on recent concepts of brain CYP function, gives an outlook on neuroactive drug use in therapy and self-medication, and highlights the endocrine side effects after drug therapy in neurological diseases and brain tumors. WHAT THE READER WILL GAIN: The reader is introduced to a CYP mediated drug-hormone crosstalk as a possible mechanism to explain these side effects. TAKE HOME MESSAGE: The drug-hormone crosstalk may be of considerable importance in the assessment of neuroactive drugs and future drug design.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20201748     DOI: 10.1517/17425251003680791

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  2 in total

1.  Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects.

Authors:  Jibran Y Khokhar; Rachel F Tyndale
Journal:  Neuropsychopharmacology       Date:  2010-11-24       Impact factor: 7.853

2.  Monocrotophos induces the expression and activity of xenobiotic metabolizing enzymes in pre-sensitized cultured human brain cells.

Authors:  Vinay K Tripathi; Vivek Kumar; Abhishek K Singh; Mahendra P Kashyap; Sadaf Jahan; Ankita Pandey; Sarfaraz Alam; Feroz Khan; Vinay K Khanna; Sanjay Yadav; Mohtshim Lohani; Aditya B Pant
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.